Acadia Pharmaceuticals | ACAD - Cash And Equivalent


Acadia Pharmaceuticals reported $956.47M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Corcept Therapeutics USD 111.04M 2.3M Jun/2026
Cytokinetics USD 255.27M 125.43M Jun/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 8.95B 3.67B Jun/2026
Incyte USD 3.98B 33.45M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Moderna USD 1.72B 185M Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Pfizer USD 976M 727M Jun/2026
Prothena USD 288.19M 41.27M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026